<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242229</url>
  </required_header>
  <id_info>
    <org_study_id>3151A1-307</org_study_id>
    <nct_id>NCT00242229</nct_id>
  </id_info>
  <brief_title>Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder</brief_title>
  <official_title>A 6 Month, Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Elderly Outpatients With Major Depressive Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR
      during 6 months of open-label treatment in elderly outpatients with major depressive
      disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the long-term safety and tolerability of DVS SR in elderly outpatients with MDD.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the long-term response of subjects receiving DVS SR for the clinical global evaluation, functionality, general well-being, pain and absence of depressive symptoms (Hamilton Psychiatric Rating Scale for Depression 17-item score &lt; or = 7).</measure>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Major Depressive Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DVS-233 SR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients men and women aged 65 years or older.

          -  Mini Mental State Examination score of 24 or above.

          -  Subjects must have a primary diagnosis of MDD based on the criteria in the Diagnostic
             and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), single or recurrent
             episode, without psychotic features, on study day 1, if depressive symptoms for at
             least 30 days prior to screening visit and minimum screening and study day -1
             (baseline) scores of 16 on the Hamilton Psychiatric Rating Scale for Depression
             (HAM-D17).

        Exclusion Criteria:

          -  Significant risk of suicide based on clinical judgment, including common suicidal
             thoughts, and suicide being considered as a possible solution, even without specific
             plans or intention.

          -  Current (within 12 months of baseline) psychoactive substance abuse or dependence
             (including alcohol), manic episode, posttraumatic stress disorder,
             obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic
             disorder as assessed by the modified Mini International Neuropsychiatric Interview
             (MINI). Current (within 12 months of baseline) generalized anxiety disorder, panic
             disorder, or social anxiety disorder as assessed by the modified MINI and considered
             by the investigator to be primary, causing a higher degree of distress or impairment
             than MDD. Presence (within 12 months of baseline) of a clinically important
             personality disorder (such as antisocial, schizotypal, histrionic, borderline,
             narcissistic). Presence of dementia.

          -  Depression associated with the presence of an organic mental disorder due to a general
             medical condition or a neurologic disorder.

        Other exclusion applies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <last_update_submitted>August 18, 2009</last_update_submitted>
  <last_update_submitted_qc>August 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2009</last_update_posted>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

